|
1
|
Parkin DM: Global cancer statistics in the
year 2000. Lancet Oncol. 2:533–543. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Raza A and Sood GK: Hepatocellular
carcinoma review: Current treatment, and evidence-based medicine.
World J Gastroenterol. 20:4115–4127. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Keating GM: Sorafenib: A review in
hepatocellular carcinoma. Target Oncol. 12:243–253. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen J, Jin R, Zhao J, Liu J, Ying H, Yan
H, Zhou S, Liang Y, Huang D, Liang X, et al: Potential molecular,
cellular and microenvironmental mechanism of sorafenib resistance
in hepatocellular carcinoma. Cancer Lett. 367:1–11. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kodura MA and Souchelnytskyi S: Breast
carcinoma metastasis suppressor gene 1 (BRMS1): Update on its role
as the suppressor of cancer metastases. Cancer Metastasis Rev.
34:611–618. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Samant RS, Seraj MJ, Saunders MM, Sakamaki
TS, Shevde LA, Harms JF, Leonard TO, Goldberg SF, Budgeon L, Meehan
WJ, et al: Analysis of mechanisms underlying BRMS1 suppression of
metastasis. Clin Exp Metastasis. 18:683–693. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Qiu R, Shi H, Wang S, Leng S, Liu R, Zheng
Y, Huang W, Zeng Y, Gao J, Zhang K, et al: BRMS1 coordinates with
LSD1 and suppresses breast cancer cell metastasis. Am J Cancer Res.
8:2030–2045. 2018.PubMed/NCBI
|
|
8
|
Rivera J, Megías D, Navas C and Bravo J:
Identification of essential sequences for cellular localization in
BRMS1 metastasis suppressor. PLoS One. 4:e64332009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chimonidou M, Strati A, Tzitzira A,
Sotiropoulou G, Malamos N, Georgoulias V and Lianidou ES: DNA
methylation of tumor suppressor and metastasis suppressor genes in
circulating tumor cells. Clin Chem. 57:1169–1177. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hicks DG, Yoder BJ, Short S, Tarr S,
Prescott N, Crowe JP, Dawson AE, Budd GT, Sizemore S, Cicek M, et
al: Loss of breast cancer metastasis suppressor 1 protein
expression predicts reduced disease-free survival in subsets of
breast cancer patients. Clin Cancer Res. 12:6702–6708. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang T, Lander ES and Sabatini DM:
Large-scale single guide RNA library construction and use for
CRISPR-Cas9-based genetic screens. Cold Spring Harb Protoc 2016.
pdb.top086892. 2016. View Article : Google Scholar
|
|
12
|
Witt-Kehati D, Fridkin A, Alaluf MB, Zemel
R and Shlomai A: Inhibition of pMAPK14 overcomes resistance to
sorafenib in hepatoma cells with hepatitis B virus. Transl Oncol.
11:511–517. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Al Dubayee MS, Alayed H, Almansour R,
Alqaoud N, Alnamlah R, Obeid D, Alshahrani A, Zahra MM, Nasr A,
Al-Bawab A and Aljada A: Differential expression of human
peripheral mononuclear cells phenotype markers in type 2 diabetic
patients and type 2 diabetic patients and type 2 diabetic patients
on metformin. Front Endocrinol (Lausanne). 9:5372018. View Article : Google Scholar
|
|
14
|
Hartke J, Johnson M and Ghabril M: The
diagnosis and treatment of hepatocellular carcinoma. Semin Diagn
Pathol. 34:153–159. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tung-Ping Poon R, Fan ST and Wong J: Risk
factors, prevention, and management of postoperative recurrence
after resection of hepatocellular carcinoma. Ann Surg. 232:10–24.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tzogani K, Skibeli V, Westgaard I, Dalhus
M, Thoresen H, Slot KB, Damkier P, Hofland K, Borregaard J, Ersbøll
J, et al: The European medicines agency approval of axitinib
(Inlyta) for the treatment of advanced renal cell carcinoma after
failure of prior treatment with sunitinib or a cytokine: Summary of
the scientific assessment of the committee for medicinal products
for human use. Oncologist. 20:196–201. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hedley BD, Vaidya KS, Phadke P, MacKenzie
L, Dales DW, Postenka CO, MacDonald IC and Chambers AF: BRMS1
suppresses breast cancer metastasis in multiple experimental models
of metastasis by reducing solitary cell survival and inhibiting
growth initiation. Clin Exp Metastasis. 25:727–740. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
You J, He X, Ding H and Zhang T: BRMS1
regulates apoptosis in non-small cell lung cancer cells. Cell
Biochem Biophys. 71:465–472. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guo XL, Wang YJ, Cui PL, Wang YB, Liang
PX, Zhang YN and Xu YQ: Effect of BRMS1 expression on
proliferation, migration and adhesion of mouse forestomach
carcinoma. Asian Pac J Trop Med. 8:724–730. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Toniato E, Frydas I, Robuffo I, Ronconi G,
Caraffa Al, Kritas SK and Conti P: Activation and inhibition of
adaptive immune response mediated by mast cells. J Biol Regul
Homeost Agents. 31:543–548. 2017.PubMed/NCBI
|
|
21
|
De Feo D, Merlini A, Brambilla E, Ottoboni
L, Laterza C, Menon R, Srinivasan S, Farina C, Garcia Manteiga JM,
Butti E, et al: Neural precursor cell-secreted TGF-β2 redirects
inflammatory monocyte-derived cells in CNS autoimmunity. J Clin
Invest. 127:3937–3953. 2017. View
Article : Google Scholar
|
|
22
|
Clark IA and Vissel B: Excess cerebral TNF
causing glutamate excitotoxicity rationalizes treatment of
neurodegenerative diseases and neurogenic pain by anti-TNF agents.
J Neuroinflammation. 13:2362016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Apert C, Romagnoli P and van Meerwijk JPM:
IL-2 and IL-15 dependent thymic development of Foxp3-expressing
regulatory T lymphocytes. Protein Cell. 9:322–332. 2018.PubMed/NCBI
|
|
24
|
Mazumder AG, Patial V and Singh D:
Mycophenolate mofetil contributes to downregulation of the
hippocampal interleukin type 2 and 1β mediated PI3K/AKT/mTOR
pathway hyperactivation and attenuates neurobehavioral
comorbidities in a rat model of temporal lobe epilepsy. Brain Behav
Immun. 75:84–93. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yan C, Deng C, Liu X, Chen Y, Ye J, Cai R,
Shen Y and Tang H: TNF-α induction of IL-6 in alveolar type II
epithelial cells: Contributions of JNK/c-Jun/AP-1 element,
C/EBPδ/C/EBP binding site and IKK/NF-κB p65/κB site. Mol Immunol.
101:585–596. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kumari N, Dwarakanath BS, Das A and Bhatt
AN: Role of interleukin-6 in cancer progression and therapeutic
resistance. Tumour Biol. 37:11553–11572. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tsujimoto Y, Finger LR, Yunis J, Nowell PC
and Croce CM: Cloning of the chromosome breakpoint of neoplastic B
cells with the t(14;18) chromosome translocation. Science.
226:1097–1099. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
D'Orsi B, Mateyka J and Prehn JHM: Control
of mitochondrial physiology and cell death by the Bcl-2 family
proteins Bax and Bok. Neurochem Int. 109:162–170. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Veis DJ, Sorenson CM, Shutter JR and
Korsmeyer SJ: Bcl-2-deficient mice demonstrate fulminant lymphoid
apoptosis, polycystic kidneys, and hypopigmented hair. Cell.
75:229–240. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chipuk JE, Moldoveanu T, Llambi F, Parsons
MJ and Green DR: The BCL-2 family reunion. Mol Cell. 37:299–310.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sedano Muñoz R, Quera Pino R, Lubascher
Correa J, Pizarro Jofré G and Simian Marín D: Evaluation of
de-escalation of anti-TNF-α therapy in inflammatory bowel disease.
Gastroenterol Hepatol. 42:133–140. 2019.(In English, Spanish).
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mortaz E, Sereshki HA, Abedini A, Kiani A,
Mirsaeidi M, Soroush D, Garssen J, Velayati A, Redegeld FA and
Adcock IM: Association of serum TNF-α, IL-8 and free light chain
with HLA-DR B alleles expression in pulmonary and extra-pulmonary
sarcoidosis. J Inflamm (Lond). 12:212015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Laplante M and Sabatini DM: mTOR signaling
in growth control and disease. Cell. 149:274–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ocana A, Vera-Badillo F, Al-Mubarak M,
Templeton AJ, Corrales-Sanchez V, Diez-Gonzalez L, Cuenca-Lopez MD,
Seruga B, Pandiella A and Amir E: Activation of the PI3K/mTOR/AKT
pathway and survival in solid tumors: Systematic review and
meta-analysis. PLoS One. 9:e952192014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ersahin T, Tuncbag N and Cetin-Atalay R:
The PI3K/AKT/mTOR interactive pathway. Mol Biosyst. 11:1946–1954.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sionov RV, Vlahopoulos SA and Granot Z:
Regulation of Bim in health and disease. Oncotarget. 6:23058–23134.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen F, Zhang L, Wu J, Huo F, Ren X, Zheng
J and Pei D: HCRP-1 regulates EGFR-AKT-BIM-mediated anoikis
resistance and serves as a prognostic marker in human colon cancer.
Cell Death Dis. 9:11762018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kasprzak A and Adamek A: The insulin-like
growth factor (IGF) signaling axis and hepatitis C virus-associated
carcinogenesis (review). Int J Oncol. 41:1919–1931. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Adamek A and Kasprzak A: Insulin-like
growth factor (IGF) system in liver diseases. Int J Mol Sci.
19(pii): E13082018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang J, Li YC, Deng M, Jiang HY, Guo LH,
Zhou WJ and Ruan B: Serum insulin-like growth factor-1 and its
binding protein 3 as prognostic factors for the incidence,
progression, and outcome of hepatocellular carcinoma: A systematic
review and meta-analysis. Oncotarget. 8:81098–81108.
2017.PubMed/NCBI
|
|
41
|
Seoane J and Gomis RR: TGF-β family
signaling in tumor suppression and cancer progression. Cold Spring
Harb Perspect Biol. 9(pii): a0222772017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Feng ZT, Yang T, Hou XQ, Wu HY, Feng JT,
Ou BJ, Cai SJ, Li J and Mei ZG: Sinomenine mitigates
collagen-induced arthritis mice by inhibiting angiogenesis. Biomed
Pharmacother. 113:1087592019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xue D, Yang Y, Liu Y, Wang P, Dai Y, Liu
Q, Chen L, Shen J, Ju H, Li Y and Tan Z: MicroRNA-206 attenuates
the growth and angiogenesis in non-small cell lung cancer cells by
blocking the 14-3-3ζ/STAT3/HIF-1α/VEGF signaling. Oncotarget.
7:79805–79813. 2016. View Article : Google Scholar : PubMed/NCBI
|
